Las Vegas, NV -- (SBWIRE) -- 12/30/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more. EquityObserver.com issues a special report on the following stocks:WidePoint Corporation(NYSEMKT:WYY),Delcath Systems, Inc.(NASDAQ:DCTH),NewLead Holdings Ltd(NASDAQ:NEWL),Mast Therapeutics Inc(NYSEMKT:MSTX)
WidePoint Corporation(NYSEMKT:WYY)managed to keep its gain at 11.54% on above-normal volume of 3.89Mshares. The stock settled at $1.74, after floating in a range of $1.56 - 1.75. Its latest price has reached market capitalization of $111.11M. Its 52-week range has been $0.34 - 1.75. WidePoint Corporation (WidePoint) is a provider of customized technology-based products and solutions to both the government sector and commercial markets.
How Should Investors Trade WYY Now?Don’t Miss out a Special Trend Analysis
Delcath Systems, Inc.(NASDAQ:DCTH)trading on a volume of 3.63Mshares, higher than its standard daily volume. Shares have been closed at$0.250. Over the last twelve months, the stock has lost-79.67% and faced a worst price of $0.22.Delcath Systems, Inc. (Delcath) is a development-stage, specialty pharmaceutical and medical device company, focused on oncology,
Is DCTH a Solid Investment at These Levels?Read This Report for Details
NewLead Holdings Ltd(NASDAQ:NEWL)is down at $1.80 on above- normal volume of 3.48Mshares during the last trading day. The stock has its 12-month range $1.14 - 122.85. Its Intraday range is $1.73 - 2.32.NewLead Holdings Ltd. (NewLead) is an international shipping company engaged in the transportation of refined products,
How Should Investors Trade NEWL Now?Don’t Miss out a Special Trend Analysis
In the last trading day, Mast Therapeutics Inc(NYSEMKT:MSTX)is on high volume, trading at a volume of versus its average daily volume ratio 3.35M/1.01Mshares. At $0.442, the stock has attained market capitalization of 45.36M.Mast Therapeutics, Inc., formerly ADVENTRX Pharmaceuticals, Inc., is a development-stage company biopharmaceutical company focused on developing product candidates. The Company's product candidate is ANX-188, a rheologic.
Will Investors Buy MSTX After Reading This News?Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)